Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes

被引:218
作者
Loftsson, Thorsteinn [1 ]
Brewster, Marcus E. [2 ]
机构
[1] Univ Iceland, Fac Pharmaceut Sci, IS-107 Reykjavik, Iceland
[2] Johnson & Johnson, Pharmaceut Dev & Mfg Sci, Janssen Res & Dev, Beerse, Belgium
关键词
absorption; complex; cyclodextrin; membrane; permeation; HYDROXYPROPYL-BETA-CYCLODEXTRIN; VITRO CORNEAL PERMEABILITY; UNSTIRRED WATER LAYER; ETHYL 4-BIPHENYLYL ACETATE; HAIRLESS MOUSE SKIN; IN-VITRO; ORAL BIOAVAILABILITY; TRANSDERMAL DELIVERY; PERCUTANEOUS-ABSORPTION; ALPHA-CYCLODEXTRIN;
D O I
10.1111/j.2042-7158.2011.01279.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Cyclodextrins are useful solubilizing excipients that have gained currency in the formulator's armamentarium based on their ability to temporarily camouflage undesirable physicochemical properties. In this context cyclodextrins can increase oral bioavailability, stabilize compounds to chemical and enzymatic degradation and can affect permeability through biological membranes under certain circumstances. This latter property is examined herein as a function of the published literature as well as work completed in our laboratories. Key findings Cyclodextrins can increase the uptake of drugs through biological barriers if the limiting barrier component is the unstirred water layer (UWL) that exists between the membrane and bulk water. This means that cyclodextrins are most useful when they interact with lipophiles in systems where such an UWL is present and contributes significantly to the barrier properties of the membrane. Furthermore, these principles are used to direct the optimal formulation of drugs in cyclodextrins. A second related critical success factor in the formulation of cyclodextrin-based drug product is an understanding of the kinetics and thermodynamics of complexation and the need to optimize the cyclodextrin amount and drug-to-cyclodextrin ratios. Drug formulations, especially those targeting compartments associated with limited dissolution (i.e. the eye, subcutaneous space, etc.), should be carefully designed such that the thermodynamic activity of the drug in the formulation is optimal meaning that there is sufficient cyclodextrin to solubilize the drug but not more than that. Increasing the cyclodextrin concentration decreases the formulation 'push' and may reduce the bioavailability of the system. Conclusions A mechanism-based understanding of cyclodextrin complexation is essential for the appropriate formulation of contemporary drug candidates.
引用
收藏
页码:1119 / 1135
页数:17
相关论文
共 245 条
[11]   Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration activation of ethyl 4-biphenylyl acetate in hairless mouse skin [J].
Arima, H ;
Miyaji, T ;
Irie, T ;
Hirayama, F ;
Uekama, K .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (01) :53-59
[12]  
Arima H, 1996, CHEM PHARM BULL, V44, P582
[13]   PAMPA - a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates [J].
Avdeef, A ;
Nielsen, PE ;
Tsinman, O .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 22 (05) :365-374
[14]   PAMPA - Critical factors for better predictions of absorption [J].
Avdeef, Alex ;
Bendels, Stefanie ;
Di, Li ;
Faller, Bernard ;
Kansy, Manfred ;
Sugano, Kiyohiko ;
Yamauchi, Yukinori .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (11) :2893-2909
[15]   Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin [J].
Babu, RJ ;
Pandit, JK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) :155-165
[16]  
BABU RJ, 1995, STP PHARMA SCI, V5, P196
[17]  
Badawy SIF, 1996, INT J PHARM, V145, P137
[18]  
Badawy SIF, 1996, INT J PHARM, V128, P45
[19]   Mucin structure, aggregation, physiological functions and biomedical applications [J].
Bansil, Rama ;
Turner, Bradley S. .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2006, 11 (2-3) :164-170
[20]   Considerations in the use of hydroxypropyl-β-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone [J].
Bary, AR ;
Tucker, IG ;
Davies, NM .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (02) :237-244